Top

Gepubliceerd in:

07-11-2018 | Artikel

Diagnostiek van de ziekte van Alzheimer

Auteur: Wiesje M. van der Flier

Gepubliceerd in: Neuropraxis | Uitgave 6/2018

Samenvatting

De ziekte van Alzheimer is de meest voorkomende oorzaak van dementie. Problemen in het episodische geheugen vormen het opvallendste kenmerk van Alzheimer. In de loop van het ziekteproces is sprake van globale cognitieve achteruitgang, problemen in het dagelijks leven en verlies van zelfstandigheid. Dit artikel gaat over de stand van zaken op het gebied van diagnostiek van alzheimer, waaronder de resultaten van het ABIDE (Alzheimer Biomarkers in Daily Practice) project, dat subsidie kreeg in het kader van het Deltaplan Dementie en nieuwe ontwikkelingen, waaronder (nieuwe) diagnostische tests om het ziekteproces al tijdens het leven aan te tonen. Verder gaat het artikel in op neuropsychologisch onderzoek, MRI, eiwitten in het hersenvocht en amyloïd PET. Ook worden de nieuwste criteria en het onderzoeksframework voor alzheimer besproken. Alzheimerhersenschade ontwikkelt zich decennia eerder dan het syndroom alzheimerdementie. Het wordt dan ook steeds duidelijker dat diagnostiek van dementie plaats moet vinden langs twee assen, die niet exact gelijk lopen: de as van etiologie ofwel hersenschade, en de as van syndroom ofwel cognitieve achteruitgang en beperkingen in het dagelijks leven. Het laatste woord is tenslotte aan de patiënt, die aangeeft graag meer informatie te willen krijgen over wat de specifieke uitslag van het diagnostisch onderzoek uitslag betekent voor zijn persoonlijke situatie.

vorige artikel De afasie van Broca en Wernicke behoren tot de geschiedenis

volgende artikel Neurowetenschappen en psychotherapie

Scheltens P, Blennow K, Breteler MM, De SB, Frisoni GB, Salloway S, Flier WM van der. Alzheimer’s disease. Lancet. 2016;388:505–17.CrossRefPubMed

Flier WM van der, Skoog I, Schneider JA, Pantoni L, Mok V, Chen CLH, Scheltens P. Vascular cognitive impairment. Nat Rev Dis Primers. 2018;4:18003.CrossRefPubMed

Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672–82.CrossRefPubMedPubMedCentral

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Baillieres Clin Neurol. 2017;89:88–100.

Wilde A de, Maurik IS van, Kunneman M, Bouwman F, Zwan M, Willemse EA, et al. Alzheimer’s biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimers Dement. 2017;6:143–51.

Flier WM van der, Pijnenburg YA, Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer’s disease: The case of the missing APOE varepsilon4 allele. Lancet Neurol. 2011;10:280–8.CrossRefPubMed

Smits LL, Pijnenburg YA, Koedam EL, Vlies AE van der, Reuling IE, Koene T, Teunissen CE, Scheltens P, Flier WM van der. Early onset Alzheimer’s disease is associated with a distinct neuropsychological profile. J Alzheimers Dis. 2012;30:101–8.CrossRefPubMed

Jutten RJ, Peeters CFW, Leijdesdorff SMJ, Visser PJ, Maier AB, Terwee CB, et al. Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimers Dement. 2017;8:26–35.

Sikkes SA, Lange-de Klerk ES de, Pijnenburg YA, Scheltens P, Uitdehaag BM. A systematic review of instrumental activities of daily living scales in dementia: Room for improvement. J Neurol Neurosurg Psychiatry. 2009;80:7–12.CrossRefPubMed

10.

Sikkes SA, de Lange-de Klerk ES, Pijnenburg YA, Gillissen F, Romkes R, Knol DL, et al. A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimers Dement. 2012;8:536–43.CrossRefPubMed

11.

Lehmann M, Koedam EL, Barnes J, Bartlett JW, Ryan NS, Pijnenburg YA, et al. Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer’s disease. Neurobiol Aging. 2011;33:e621–7.

12.

Moller C, Vrenken H, Jiskoot L, Versteeg A, Barkhof F, Scheltens P, et al. Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease. Neurobiol Aging. 2013;34:2014–22.CrossRefPubMed

13.

Cordonnier C, Flier WM van der. Brain microbleeds and Alzheimer’s disease: Innocent observation or key player? Brain. 2011;134:335–44.CrossRefPubMed

14.

Goos JD, Kester MI, Barkhof F, Klein M, Blankenstein MA, Scheltens P, et al. Patients with Alzheimer disease with multiple microbleeds: Relation with cerebrospinal fluid biomarkers and cognition. Stroke. 2009;40:3455–60.CrossRefPubMed

15.

Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement. 2017;8:111–26.

16.

Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2003;2:605–13.CrossRefPubMed

17.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58:373–9.CrossRefPubMed

18.

Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–44.CrossRefPubMed

19.

Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, et al. The cerebrospinal fluid ‘Alzheimer profile’: Easily said, but what does it mean? Alzheimers Dement. 2014;10:713–23.CrossRefPubMed

20.

Duits FH, Prins ND, Lemstra AW, Pijnenburg YA, Bouwman FH, Teunissen CE, et al. Diagnostic impact of CSF biomarkers for Alzheimer’s disease in a tertiary memory clinic. Alzheimers Dement. 2015;11:523–32.CrossRefPubMed

21.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385–93.CrossRefPubMed

22.

Babapour Mofrad R, Bouwman FH, Slot RER, Timmers T, Flier WM van der, Scheltens P, et al. Lumbar puncture in patients with neurologic conditions. Alzheimers Dement. 2017;8:108–10.

23.

Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, Berckel BNM van, Scheltens P, et al. Plasma amyloid as pre-screener for the earliest Alzheimer’s pathological changes. Ann Neurol. 2018 Sep 9. Epub ahead of print.CrossRefPubMedPubMedCentral

24.

Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, Westen D van, Jeromin A, et al. Plasma beta-amyloid in Alzheimer’s disease and vascular disease. Sci Rep. 2016;6(1):26801.CrossRefPubMedPubMedCentral

25.

Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature. 2018;554:249–54.CrossRefPubMed

26.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.CrossRefPubMed

27.

Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, Flier WM van der, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9:414–21.CrossRefPubMed

28.

Zwan MD, Bouwman FH, Konijnenberg E, Flier WM van der, Lammertsma AA, Verhey FR, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9:2.CrossRefPubMedPubMedCentral

29.

Altomare D, Ferrari C, Festari C, Guerra UP, Muscio C, Padovani A, et al. Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET. Alzheimers Dement. 2018;14(8):1088–98.CrossRefPubMed

30.

Wilde A de, Flier WM van der, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of Amyloid positron emission Tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: The ABIDE project. Jama Neurol. 2018;75(9):1062.CrossRefPubMedPubMedCentral

31.

Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9(1):E1–16.CrossRef

32.

Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457–68.CrossRefPubMed

33.

APA. Diagnostic and statistical manual of mental disorders (DSM IV). Washington, DC: APA; 1994.

34.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Baillieres Clin Neurol. 1984;34:939–44.

35.

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.CrossRefPubMedPubMedCentral

36.

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9.CrossRefPubMedPubMedCentral

37.

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92.CrossRefPubMedPubMedCentral

38.

Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.CrossRefPubMedPubMedCentral

39.

Reisberg B, Ferris SH, Leon MJ de, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136–9.CrossRefPubMed

40.

Maurik IS van, Zwan M, Tijms B, Bouwman F, Teunissen C, Scheltens P, et al. Interpreting Biomarker results in individual patients with mild cognitive impairment in the Alzheimer’s Biomarkers in daily practice (ABIDE) project. Jama Neurol. 2017;74(12):1481.CrossRefPubMedPubMedCentral

41.

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA. 2015;313:1924–38.CrossRefPubMedPubMedCentral

42.

Jessen F, Amariglio RE, Boxtel M van, Breteler M, Ceccaldi M, Chetelat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844–52.CrossRefPubMedPubMedCentral

43.

Harten AC van, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, et al. Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 2013;9(5):481–7.CrossRefPubMed

44.

Flier WM van der, Kunneman M, Bouwman F, Petersen RC, Smets EM. Diagnostic dilemmas in Alzheimer’s disease: Room for shared decision making. Alzheimers Dement. 2017;3(3):301–4.CrossRef

45.

Kunneman M, Smets EM, Bouwman F, Schoonenboom N, Zwan M, et al. Clinicians’ views on conversations and shared decision making in diagnostic testing for Alzheimer’s disease: The ABIDE project. Alzheimers Dement. 2017;3(3):305–13.CrossRef

46.

Kunneman M, Pel R, Bouwman FH, Gillissen F, Schoonenboom N, Claus JJ, et al. Patients’ and caregivers’ views on conversations and shared decision making in diagnostic testing for Alzheimer’s disease: The ABIDE project. Alzheimers Dement. 2017;3(3):314–22.CrossRef

Titel: Diagnostiek van de ziekte van Alzheimer
Auteur: Wiesje M. van der Flier
Publicatiedatum: 07-11-2018
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Neuropraxis / Uitgave 6/2018
Print ISSN: 1387-5817
Elektronisch ISSN: 1876-5785
DOI: https://doi.org/10.1007/s12474-018-00205-z

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 6/2018

Woorden vooraf

De afasie van Broca en Wernicke behoren tot de geschiedenis

Neurowetenschappen en psychotherapie

De ontstoken geest